Updated Clinical Guideline for Human Papillomavirus Vaccine: the Korean Society of Gynecologic Oncology Guidelines

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2021 Oct 28

PMID 34708596

Citations 1

Authors

Hyun-Woong Cho

Kyung-Jin Min

Sang-Hoon Kwon

Kidong Kim

Sunghoon Kim

Seok Ju Seong

Yong Jung Song

Keun Ho Lee

Shin-Wha Lee

Jeong-Won Lee

Woong Ju

Young Tae Kim

Jae Kwan Lee

Affiliations

Soon will be listed here.

Abstract

Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies on the efficacy and safety of HPV vaccines in middle-aged women and men have been reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV vaccine in women with prior HPV infection or who have undergone conization for cervical intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in patients infected with HPV and those who underwent conization for CIN. The KSGO updated their guidelines based on the results of the studies included in this review.

Citing Articles

Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines.

Yoo J, Lee S, Nam E, No J, Park J, Song J J Gynecol Oncol. 2024; 35(2):e44.

PMID: 38389404 PMC: 10948982. DOI: 10.3802/jgo.2024.35.e44.

References

Meites E, Kempe A, Markowitz L . Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016; 65(49):1405-1408. DOI: 10.15585/mmwr.mm6549a5. View

Schwarz T, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K . Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin. 2011; 7(9):958-65. PMC: 3225769. DOI: 10.4161/hv.7.9.15999. View

Kang W, Choi H, Kim S . Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecol Oncol. 2013; 130(2):264-8. DOI: 10.1016/j.ygyno.2013.04.050. View

Lichter K, Krause D, Xu J, Tsai S, Hage C, Weston E . Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet Gynecol. 2020; 135(5):1070-1083. DOI: 10.1097/AOG.0000000000003833. View

Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S . Human papillomavirus and cervical cancer. Lancet. 2007; 370(9590):890-907. DOI: 10.1016/S0140-6736(07)61416-0. View

Ojha R, Jackson B, Tota J, Offutt-Powell T, Singh K, Bae S . Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother. 2013; 10(1):232-7. PMC: 4181024. DOI: 10.4161/hv.26292. View

Yoon D, Lee J, Lee H, Shin J . Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. BMJ. 2021; 372:m4931. PMC: 8030229. DOI: 10.1136/bmj.m4931. View

Scheller N, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K . Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015; 313(1):54-61. DOI: 10.1001/jama.2014.16946. View

Meites E, Szilagyi P, Chesson H, Unger E, Romero J, Markowitz L . Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68(32):698-702. PMC: 6818701. DOI: 10.15585/mmwr.mm6832a3. View

10.

Karimi-Zarchi M, Allahqoli L, Nehmati A, Kashi A, Taghipour-Zahir S, Alkatout I . Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial. BMC Public Health. 2020; 20(1):274. PMC: 7045378. DOI: 10.1186/s12889-020-8371-z. View

11.

Bray F, Ferlay J, Laversanne M, Brewster D, Gombe Mbalawa C, Kohler B . Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015; 137(9):2060-71. DOI: 10.1002/ijc.29670. View

12.

Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Galaj A, Schulze K . Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG. 2014; 122(1):107-18. PMC: 4489326. DOI: 10.1111/1471-0528.13070. View

13.

Ault K . Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369(9576):1861-1868. DOI: 10.1016/S0140-6736(07)60852-6. View

14.

Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

15.

Konno R, Shin H, Kim Y, Song Y, Sasagawa T, Inoue M . Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine. 2008; 26 Suppl 12:M30-42. DOI: 10.1016/j.vaccine.2008.05.006. View

16.

Schlecht N, Masika M, Diaz A, Nucci-Sack A, Salandy A, Pickering S . Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Netw Open. 2019; 2(10):e1914031. PMC: 6822084. DOI: 10.1001/jamanetworkopen.2019.14031. View

17.

Wei L, Xie X, Liu J, Zhao Y, Chen W, Zhao C . Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. Vaccine. 2018; 37(27):3617-3624. DOI: 10.1016/j.vaccine.2018.08.009. View

18.

Garland S, Kjaer S, Munoz N, Block S, Brown D, DiNubile M . Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016; 63(4):519-27. PMC: 4967609. DOI: 10.1093/cid/ciw354. View

19.

Garland S, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow S . Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer. 2016; 139(12):2812-2826. PMC: 5412942. DOI: 10.1002/ijc.30391. View

20.

Leung T, Liu A, Lim F, Thollot F, Oh H, Lee B . Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother. 2015; 11(7):1689-702. PMC: 4514190. DOI: 10.1080/21645515.2015.1050570. View